Summary
In this review, we have highlighted recent advances in chronic lymphoproliferative disorders that commonly involve the peripheral blood. As we have seen, our concepts of certain diseases are changing. Molecular genetic and immunophenotypic studies are allowing more precise characterization of CLL and defining important biologic markers that predict clinical behavior. Prolymphocytic leukemia is now more narrowly defined and its relationship to nucleolated variants of MCL is now apparent. With new reagents and techniques applied to problems such as identification of Sezary cells and T-cell monoclonality determination, our ability to diagnose, monitor, and provide prognostic information is improving. Insight into the biology of these diseases also may provide new therapeutic targets in the future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Oscier DG, Matutes E, Copplestone A et al. Atypical lymphocyte morphology: an adverse prognostic factor for disease progression in stage A CLL independent of trisomy 12. Br J Haematol. 1997;98:934–939
Matutes E, Oscier D, Garcia-Marco J et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients. Br J Haematol. 1996;92:382–388
Frater JL, McCarron KF, Hammel JP et al. Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. Am J Clin Pathol. 2001;116:655–664
Criel A, Verhoef G, Vlietinck R et al. Further characterization of morphologically defined typical and atypical CLL: a clinical, immunophenotypic, cytogenetic and prognostic study on 390 cases. Br J Haematol. 1997;97:383–391
Vallespi T, Montserrat E, Sanz MA. Chronic lymphocytic leukaemia: prognostic value of lymphocyte morphological subtypes. A multivariate survival analysis in 146 patients. Br J Haematol. 1991;77:478–485
Cheson BD, Bennett JM, Rai KR et al. Guidlines for clincial protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-Sponsored Working Group. Am J Hematol. 1988;29:152–163
Cheson BD, Bennett JM, Grever M et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87:4990–4997
Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234
Dohner H, Stilgenbauer S, Dohner K et al. Chromosome aberrations in B-cell chronic lymphocytic leukemia: reassessment based on molecular cytogenetic analysis. J Mol Med. 1999;77:266–281
Finn WG, Thangavelu M, Yelavarthi KK et al. Karyotype correlates with peripheral blood morphology and immunophenotype in chronic lymphocytic leukemia. Am J Clin Pathol. 1996;105:458–467
Dohner H, Stilgenbauer S, Benner A et al. Genomic alterations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916
Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression As novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847
Hamblin TJ, Davis Z, Gardiner A et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854
Meeker TC, Grimaldi JC, O’Rourke R et al. Lack of detectable somatic hypermutation in the V region of the Ig H chain gene of a human chronic B lymphocytic leukemia. J Immunol. 1988;141:3994–3998
Hamblin T. Chronic lymphocytic leukaemia: one disease or two? Ann Hematol. 2002;81:299–303
Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–1647
D’Arena G, Musto P, Cascavilla N et al. CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chornic lymphocytic leukemia. Leuk Lymphoma. 2001;42:109–114
Ibrahim S, Keating M, Do KA et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001;98:181–186
Jelinek DF, Tschumper RC, Geyer SM et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115:854–861
Krober A, Seiler T, Benner A et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410–1416
Hamblin TJ, Orchard JA, Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood. 2002;99:1023–1029
Lin K, Sherrington PD, Dennis M et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood. 2002;100:1404–1409
Mainou-Fowler T, Dignum H, Taylor PR et al. Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. Br J Haematol. 2002;118:755–761
Hsi ED, Kopecky KJ, Appelbaum FR et al. Prognostic Significance of CD38 and CD20 Expression as Assessed by Quantitative Flow Cytometry in Chronic Lymphocytic Leukemia (CLL). Br J Haematol. 2003;120:1017–1025
Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348:1764–1775
Wiestner A, Rosenwald A, Barry TS et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003
Ott G, Kalla J, Hanke A et al. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Leuk Lymphoma. 1998;32:55–63
Argatoff LH, Connors JM, Klasa RJ et al. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood. 1997;89:2067–2078
Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of chronic (mature) B and T lymphoid leukaemias. French-American-British (FAB) Cooperative Group. J Clin Pathol. 1989;42:567–584
Schlette E, Bueso-Ramos C, Giles F et al. Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma. Am J Clin Pathol. 2001;115:571–581
Dalton DAG, Goldman JM, Wiltshaw E et al. Prolymphocytic leukemia. Br J Haematol. 1974;27:7–23
Jaffe ES, Harris NL, Stein H et al. Tumours of Haematopoeitic and Lymphoid Tissues. 2001; Lyon: IARC Press
Matutes E, Owusu-Ankomah K, Morilla R et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640–1645
Wong KF, So CC, Chan JK. Nucleolated variant of mantle cell lymphoma with leukemic manifestations mimicking prolymphocytic leukemia. Am J Clin Pathol. 2002;117:246–251
Dunphy CH, Perkins SL. Mantle cell leukemia, prolymphocytoid type: a rarely described form. Leuk Lymphoma. 2001;41:683–687
Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003;101:2464–2472
Mateo M, Mollejo M, Villuendas R et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol. 1999;154:1583–1589
Gruszka-Westwood AM, Matutes E, Coignet LJ et al. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol. 1999;104:600–604
Oscier DG, Matutes E, Gardiner A et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol. 1993;85:487–491
Hernandez JM, Garcia JL, Gutierrez NC et al. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol. 2001;158:1843–1850
Sole F, Salido M, Espinet B et al. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica. 2001;86:71–77
Hernandez JM, Mecucci C, Criel A et al. Cytogenetic analysis of B cell chronic lymphoid leukemias classified according to morphologic and immunophenotypic (FAB) criteria. Leukemia. 1995;9:2140–2146
Gruszka-Westwood AM, Hamoudi R, Osborne L et al. Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes. Genes Chromosomes Cancer. 2003;36:57–69
Corcoran MM, Mould SJ, Orchard JA et al. Dysregulation of cyclin dependent kinase 6 expression in splenic marginal zone lymphoma through chromosome 7q translocations. Oncogene. 1999;18:6271–6277
Algara P, Mateo MS, Sanchez-Beato M et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood. 2002;99:1299–1304
Bahler DW, Pindzola JA, Swerdlow SH. Splenic marginal zone lymphomas appear to originate from different B cell types. Am J Pathol. 2002;161:81–88
Dunn-Walters DK, Boursier L, Spencer J et al. Analysis of immunoglobulin genes in splenic marginal zone lymphoma suggests ongoing mutation. Hum Pathol. 1998;29:585–593
Bahler DW, Miklos JA, Swerdlow SH. Ongoing Ig gene hypermutation in salivary gland mucosa-associated lymphoid tissue-type lymphomas. Blood. 1997;89:3335–3344
Taswell H, Winkelmann R. Sezary syndrome — a malignant reticulemic erythroderma. JAMA. 1961;117:465–472
Vonderheid EC, Bernengo MG, Burg G et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46:95–106
Flandrin G, Brouet JC. The Sezary cell: cytologic, cytochemical, and immunologic studies. Mayo Clin Proc. 1974;49:575–583
Hoppe RT, Wood GS, Abel EA. Mycosis fungoides and the Sezary syndrome: pathology, staging, and treatment. Curr Probl Cancer. 1990;14:293–371
Kim YH, Bishop K, Varghese A et al. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol. 1995;131:1003–1008
Scarisbrick JJ, Whittaker S, Evans AV et al. Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood. 2001;97:624–630
Bunn PA, Jr., Huberman MS, Whang-Peng J et al. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med. 1980;93:223–230
Lamberg SI, Bunn PA, Jr. Cutaneous T-Cell Lymphomas: Summary of the mycosis fungoides cooperative group-national cancer institute workshop. Arch Dermatol. 1979;115:1103–1105
Vonderheid EC, Sobel EL, Nowell PC et al. Diagnostic and prognostic significance of Sezary cells in peripheral blood smears from patients with cutaneous T cell lymphoma. Blood. 1985;66:358–366
Kim YH, Bishop K, Varghese A et al. Prognostic factors in erythrodermic mycosis fungoides and the Sezary syndrome. Arch Dermatol. 1995;131:1003–1008
Schechter GP, Sausville EA, Fischmann AB et al. Evaluation of circulating malignant cells provides prognostic information in cutaneous T cell lymphoma. Blood. 1987;69:841–849
Fraser-Andrews EA, Russell-Jones R, Woolford AJ et al. Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sezary syndrome. Cancer. 2001;92:1745–1752
Duncan SC, Winkelmann RK. Circulating Sezary cells in hospitalized dermatology patients. Br J Dermatol. 1978;99:171–178
Winkelmann RK, Diaz-Perez JL, Buechner SA. The treatment of Sezary syndrome. J Am Acad Dermatol. 1984;10:1000–1004
Winkelmann RK, Peters MS. Absolute number of circulatory sezary cells. Arch Dermatol. 1981;117:382
Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997;90:354–371
Bogen SA, Pelley D, Charif M et al. Immunophenotypic identification of Sezary cells in peripheral blood. Am J Clin Pathol. 1996;106:739–748
Harmon CB, Witzig TE, Katzmann JA et al. Detection of circulating T cells with CD4+CD7-immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol. 1996;35:404–410
Vonderheid EC, Bigler RD, Kotecha A et al. Variable CD7 expression on T cells in the leukemic phase of cutaneous T cell lymphoma (Sezary syndrome). J Invest Dermatol. 2001;117:654–662
Bernengo MG, Novelli M, Quaglino P et al. The relevance of the CD4+ CD26-subset in the identification of circulating Sezary cells. Br J Dermatol. 2001;144:125–135
Jones D, Dang NH, Duvic M et al. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885–892
Beck RC, Stahl S, O’Keefe CL et al. Detection of mature T cell leukemias by flow cytometry using anti-T cell receptor Vβ antibodies. Am J Clin Pathol. 2003; In Press
Ingen-Housz-Oro S, Bussel A, Flageul B et al. A prospective study on the evolution of the T-cell repertoire in patients with Sezary syndrome treated by extracorporeal photopheresis. Blood. 2002;100:2168–2174
Schwab C, Willers J, Niederer E et al. The use of anti-T-cell receptor-Vbeta antibodies for the estimation of treatment success and phenotypic characterization of clonal T-cell populations in cutaneous T-cell lymphomas. Br J Haematol. 2002;118:1019–1026
Washington LT, Huh YO, Powers LC et al. A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol. 2002;2:5
Beylot-Barry M, Sibaud V, Thiebaut R et al. Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas. J Invest Dermatol. 2001;117:920–926
Weinberg JM, Jaworsky C, Benoit BM et al. The clonal nature of circulating Sezary cells. Blood. 1995;86:4257–4262
Muche JM, Lukowsky A, Heim J et al. Demonstration of frequent occurrence of clonal T cells in the peripheral blood but not in the skin of patients with small plaque parapsoriasis. Blood. 1999;94:1409–1417
Eriksen KW, Kaltoft K, Mikkelsen G et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells. Leukemia. 2001;15:787–793
Leon F, Cespon C, Franco A et al. SHP-1 expression in peripheral T cells from patients with Sezary syndrome and in the T cell line HUT-78: implications in JAK3-mediated signaling. Leukemia. 2002;16:1470–1477
Brender C, Nielsen M, Kaltoft K et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood. 2001;97:1056–1062
Bartlett NL, Longo DL. T-small lymphocyte disorders. Semin Hematol. 1999;36:164–170
Matutes E, Brito-Babapulle V, Swansbury J et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood. 1991;78:3269–3274
Soulier J, Pierron G, Vecchione D et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2001;31:248–254
Matutes E, Catovsky D. Similarities between T-cell chronic lymphocytic leukemia and the small-cell variant of T-prolymphocytic leukemia. Blood. 1996;87:3520–3521
Berliner N. T gamma lymphocytosis and T cell chronic leukemias. Hematol Oncol Clin North Am. 1990;4:473–487
Garand R, Goasguen J, Brizard A et al. Indolent course as a relatively frequent presentation in T-prolymphocytic leukaemia. Groupe Francais ďHematologie Cellulaire. Br J Haematol. 1998;103:488–494
Hoyer JD, Ross CW, Li CY et al. True T-cell chronic lymphocytic leukemia: a morphologic and immunophenotypic study of 25 cases. Blood. 1995;86:1163–1169
Soma L, Cornfield DB, Prager D et al. Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia? Am J Hematol, 2002;71:224–226
Dearden CE, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol. 2002;19 Suppl:S27–S32
Dearden CE, Matutes E, Cazin B et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721–1726
Tuset E, Matutes E, Brito-Babapulle V et al. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia. Leuk Lymphoma. 2001;42:1379–1383
McKenna RW, Parkin J, Kersey JH et al. Chronic lymphoproliferative disorder with unusual clinical, morphologic, ultrastructural and membrane surface marker characteristics. Am J Med. 1977;62:588–596
Loughran TP, Jr., Kadin ME, Starkebaum G et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985;102:169–175
Loughran TP, Jr. Clonal diseases of large granular lymphocytes. Blood. 1993;82:1–14
Karadimitris A, Li K, Notaro R et al. Association of clonal T-cell large granular lymphocyte disease and paroxysmal nocturnal haemoglobinuria (PNH): further evidence for a pathogenetic link between T cells, aplastic anaemia and PNH. Br J Haematol. 2001;115:1010–1014
Lamy T, Loughran TP, Jr. Current concepts: large granular lymphocyte leukemia. Blood Rev. 1999;13:230–240
Chan WC, Catovsky D, Foucar K et al. T-cell large granular lymphocyte leukemia. In: Jaffe ES, Harris NL, Stein H et al., eds. Tumours of Haematopoietic and Lymphoid Tissues. 2001;Lyon: IARC Press
Semenzato G, Zambello R, Starkebaum G et al. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89:256–260
Langerak AW, van Den BR, Wolvers-Tettero IL et al. Molecular and flow cytometric analysis of the Vbeta repertoire for clonality assessment in mature TCRalphabeta T-cell proliferations. Blood. 2001;98:165–173
Evans HL, Burks E, Viswanatha D et al. Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocyte leukemia. Hum Pathol. 2000;31:1266–1273
Morice WG, Kurtin PJ, Tefferi A et al. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood. 2002;99:268–274
Lima M, Almeida J, Santos AH et al. Immunophenotypic analysis of the TCR-Vbeta repertoire in 98 persistent expansions of CD3(+)/TCR-alphabeta(+) large granular lymphocytes: utility in assessing clonality and insights into the pathogenesis of the disease. Am J Pathol. 2001;159:1861–1868
Ingen-Housz-Oro S, Bussel A, Flageul B et al. A prospective study on the evolution of the T-cell repertoire in patients with Sezary syndrome treated by extracorporeal photopheresis. Blood. 2002;100:2168–2174
Rabbani GR, Phyliky RL, Tefferi A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol. 1999;106:960–966
Morice WG, Leibson PJ, Tefferi A. Natural killer cells and the syndrome of chronic natural killer cell lymphocytosis. Leuk Lymphoma. 2001;41:277–284
Imamura N, Kusunoki Y, Kawa-Ha K et al. Aggressive natural killer cell leukaemia/lymphoma: report of four cases and review of the literature. Possible existence of a new clinical entity originating from the third lineage of lymphoid cells. Br J Haematol. 1990;75:49–59
Zambello R, Trentin L, Ciccone E et al. Phenotypic diversity of natural killer (NK) populations in patients with NK-type lymphoproliferative disease of granular lymphocytes. Blood. 1993;81:2381–2385
Morice WG, Hanson CA, Tefferi A et al. Demonstration of aberrant T and NK cell antigen expression in all cases of granular lymphocytic leukemia. Mod Pathol. 2002;15:256a
Lamy T, Liu JH, Landowski TH et al. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood. 1998;92:4771–4777
Epling-Burnette PK, Liu JH, Catlett-Falcone R et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J Clin Invest. 2001;107:351–362
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Kluwer Academic Publishers
About this chapter
Cite this chapter
Hsi, E.D., Frater, J.L. (2004). Advances in the Diagnosis and Classification of Chronic Lymphoproliferative Disorders. In: Finn, W.G., Peterson, L.C. (eds) Hematopathology in Oncology. Cancer Treatment and Research, vol 121. Springer, Boston, MA. https://doi.org/10.1007/1-4020-7920-6_6
Download citation
DOI: https://doi.org/10.1007/1-4020-7920-6_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4020-7919-1
Online ISBN: 978-1-4020-7920-7
eBook Packages: Springer Book Archive